CLDX Celldex Therapeutics

Celldex Therapeutics to Present at Upcoming Healthcare Conferences

Celldex Therapeutics to Present at Upcoming Healthcare Conferences

HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global Healthcare Conference and the HC Wainwright & CO 22nd Annual Global Investment Virtual Conference. Presentation details are as follows:

  • Cantor Virtual Global Healthcare Conference Fireside Chat: September 15, 2020 at 10:40 AM ET
  • HC Wainwright & CO 22nd Annual Global Investment Virtual Conference Fireside Chat: September 16, 2020 at 9:00 AM ET

Webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Replays will be available for fourteen days following the event.

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit .

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

Celldex Therapeutics, Inc.

(781) 433-3161

EN
10/09/2020

Underlying

CLDXCelldex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celldex Therapeutics

 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolim...

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical benefit in patients in ColdU and SD in a large, randomized, placebo-controlled study--all primary and secondary endpoints met with high statistical significance at 12 weeks and sustained through end of treatment period (20 weeks) in Phase 2 studyInitiation of EMBARQ-ColdU and SD ma...

December 9, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports Third Quarter 2025 Financial Results and Provides Corp...

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control post treatment and strong efficacy regardless of baseline IgE levels Positive Phase 2 barzolvolimab data in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) demonstrating sustained efficacy and favorable safety profile at 20 weeks; first large, randomized, placebo-controlled study to ...

November 10, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Announces Appointment of Teri Lawver as Chief Commercial Offic...

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical device and consumer health technology sectors. Ms. Lawver succeeds Richard Wright, who will retire from Celldex following more than a decade of dedicated leadership and service. “...

November 10, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex to Present at Upcoming Investor Conferences

Celldex to Present at Upcoming Investor Conferences HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11 at 10:00 am ETTD Cowen Immunology & Inflammation Summit on Thursday, November 13 at 9:30 am ET8th Annual Evercore Healthcare Conference on Tuesday, December 2 at 3:00 pm ET Live webcasts of the presentations will be available on the "" page of the "Investors" section of t...

November 7, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urti...

Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20 First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD)All primary and secondary endpoints met with high statistical significance at 12 weeks and sustained through end of treatment...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch